- Home
- BE vs GRFS Comparison
BE vs GRFS Comparison
Compare BE & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BE
- GRFS
- Stock Information
- Founded
- BE 2001
- GRFS 1940
- Country
- BE United States
- GRFS Spain
- Employees
- BE N/A
- GRFS N/A
- Industry
- BE Industrial Machinery/Components
- GRFS Biotechnology: Pharmaceutical Preparations
- Sector
- BE Energy
- GRFS Health Care
- Exchange
- BE Nasdaq
- GRFS Nasdaq
- Market Cap
- BE 5.5B
- GRFS 5.1B
- IPO Year
- BE 2018
- GRFS 2006
- Fundamental
- Price
- BE $20.34
- GRFS $7.27
- Analyst Decision
- BE Buy
- GRFS
- Analyst Count
- BE 18
- GRFS 0
- Target Price
- BE $24.67
- GRFS N/A
- AVG Volume (30 Days)
- BE 6.3M
- GRFS 1.2M
- Earning Date
- BE 05-08-2025
- GRFS 01-01-0001
- Dividend Yield
- BE N/A
- GRFS N/A
- EPS Growth
- BE N/A
- GRFS 283.33
- EPS
- BE N/A
- GRFS 0.24
- Revenue
- BE $1,473,856,000.00
- GRFS $7,467,006,939.00
- Revenue This Year
- BE $20.03
- GRFS $8.45
- Revenue Next Year
- BE $20.86
- GRFS $7.08
- P/E Ratio
- BE N/A
- GRFS $35.67
- Revenue Growth
- BE 10.53
- GRFS 9.41
- 52 Week Low
- BE $9.02
- GRFS $5.79
- 52 Week High
- BE $29.83
- GRFS $9.96
- Technical
- Relative Strength Index (RSI)
- BE 36.34
- GRFS 37.73
- Support Level
- BE $22.39
- GRFS $7.13
- Resistance Level
- BE $26.53
- GRFS $7.81
- Average True Range (ATR)
- BE 1.57
- GRFS 0.24
- MACD
- BE -0.34
- GRFS -0.11
- Stochastic Oscillator
- BE 4.77
- GRFS 13.33
About BE Bloom Energy Corporation
Bloom Energy designs, manufactures, sells, and installs solid-oxide fuel cell systems ("Energy Servers") for on-site power generation. Bloom Energy Servers are fuel-flexible and can use natural gas, biogas, and hydrogen to create 24/7 electricity for stationary applications. In 2021, the company announced plans to leverage its technology and enter the electrolyzer market. Bloom primarily sells its systems in the United States and internationally.
About GRFS Grifols S.A.
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.